No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
100 |
4. Check minimum number of eventsNone |
100 |
5. Include endpointsNone |
100 |
6. Filter based on genotype QC (FinnGen only) |
97 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Lordosis
based on the number of shared cases.
Similar with more cases:
- Deforming dorsopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 734 | 405 | 324 |
| Only index persons | 657 | 367 | 290 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.32 | 51.11 | 46.88 |
| Only index persons | 48.27 | 50.05 | 46.00 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 97 | 53 | 44 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 48.50 | 47.41 | 49.81 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 100
- Matched controls
- 1000
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M40.5
ICD-10 Finland
Lordosis, unspecified
+∞
74.6
62
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
19.0
48.5
50
50
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
128.4
43.3
44
6
L40.5
ICD-10 Finland
Arthropathic psoriasis
177.7
42.7
42
*
A07EC01
ATC
sulfasalazine; oral, rectal
21.9
39.3
33
22
L04AX03
ATC
methotrexate; systemic
13.0
31.9
38
45
L01BA01
ATC
methotrexate; systemic
54.6
24.2
28
7
M07.3
ICD-10 Finland
Other psoriatic arthropathies
294.8
23.7
23
*
D07XC01
ATC
betamethasone; topical
9.3
23.1
35
55
D05AX02
ATC
calcipotriol; topical
33.4
22.4
29
12
D05AX52
ATC
calcipotriol, combinations; topical
15.8
17.5
29
25
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
43.6
17.5
21
6
E000001, ,
ATC
5.9
16.2
40
101
L40.0
ICD-10 Finland
Psoriasis vulgaris
19.3
15.9
24
16
L04AA13
ATC
[U] leflunomide
54.2
15.7
18
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
38.5
15.5
19
6
M40.4
ICD-10 Finland
Other lordosis
+∞
15.0
14
*
7372A
ICD-9 Finland
Curvature of spine, Lordosis (acquired)
+∞
13.9
13
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
12.4
13.7
25
26
M48.0
ICD-10 Finland
Spinal stenosis
47.0
13.6
16
*
N03AX16
ATC
[U] pregabalin
5.8
13.2
30
69
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
37.6
13.0
16
5
L04AB01
ATC
etanercept; parenteral
80.4
12.9
14
*
D07AD01
ATC
clobetasol; topical
5.2
12.6
33
86
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
10.7
11.9
23
27
D07AC01
ATC
betamethasone; topical
4.3
11.8
55
223
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
11.7
11
*
N02AX02
ATC
tramadol; systemic, rectal
4.2
11.7
54
217
D05AX03
ATC
calcitriol; topical
40.2
11.6
14
*
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
29.0
11.5
15
6
H02AB06
ATC
prednisolone; systemic
4.4
11.4
67
317
L04AA01
ATC
[U] ciclosporin
122.3
10.6
11
*
E0000UV, ,
ATC
4.0
10.6
60
273
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
9.5
9
*
M073, M405,
ICD-10 Finland
+∞
9.5
9
*
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
9.5
9
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
12.4
9.2
16
15
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.9
9.1
23
57
L88
ICPC
Rheumatoid/seropositive arthritis
13.3
8.9
15
13
M17.1
ICD-10 Finland
Other primary gonarthrosis
4.0
8.6
31
101
E000002, ,
ATC
4.7
8.2
22
57
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
16.8
7.9
12
8
D07AC13
ATC
mometasone; topical
3.5
7.9
39
156
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
5.0
7.9
19
45
N03AX12
ATC
[U] gabapentin; oral
4.8
7.8
20
50
M02AA10
ATC
ketoprofen; topical
4.3
7.5
22
61
SPAT1229
SPAT
Assessment of need for aid
9.1
7.4
15
19
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
+∞
7.4
7
*
M54.4
ICD-10 Finland
Lumbago with sciatica
4.4
7.4
21
57
M43.1
ICD-10 Finland
Spondylolisthesis
32.6
7.3
9
*
L04AB04
ATC
adalimumab; parenteral
32.6
7.3
9
*
M01CB01
ATC
sodium aurothiomalate; parenteral
43.1
6.9
8
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
43.1
6.9
8
*
D05AA
ATC
Tars
43.1
6.9
8
*
M17.5
ICD-10 Finland
Other secondary gonarthrosis
43.1
6.9
8
*
L04AD01
ATC
ciclosporin; systemic
43.1
6.9
8
*
J01DA09
ATC
[U] cefadroxil
3.2
6.8
36
149
J01FF01
ATC
clindamycin; systemic
3.1
6.7
39
171
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
7.2
6.5
15
24
M54.5
ICD-10 Finland
Low back pain
3.1
6.5
36
153
M43.0
ICD-10 Finland
Spondylolysis
+∞
6.3
6
*
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
+∞
6.3
6
*
D07AB02
ATC
hydrocortisone butyrate; topical
3.0
6.3
38
169
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.8
6.2
51
268
SPAT1254
SPAT
Administration of medicine
3.8
6.1
21
65
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
60
328
3.07
6.98
6.9
4.3
0.00
0.00
estimate
—
9
61
73
454
3.25
6.61
16.0
9.8
3.78
4.04
e9/l
0.68
68
392
83
566
3.74
6.27
9.3
3.3
14.00
10.40
mm/h
1.57
78
518
59
333
2.88
6.26
5.4
3.0
0.00
0.00
estimate
—
6
58
57
327
2.73
5.69
5.5
3.1
0.00
0.00
estimate
—
9
63
42
229
2.44
4.39
5.7
2.6
—
—
—
0
0
49
300
2.24
3.80
6.4
4.2
34.48
35.65
g/l
0.85
44
282
8
12
7.13
3.75
1.4
1.1
—
—
—
0
0
49
305
2.19
3.60
7.8
4.7
1.23
1.22
mmol/l
0.41
43
284
50
322
2.11
3.29
21.1
9.7
1.56
1.23
inr
0.69
11
107
51
332
2.09
3.26
10.3
6.0
1.23
1.22
mmol/l
0.60
44
288
31
168
2.22
3.14
6.6
3.3
0.00
0.00
estimate
—
9
59
12
37
3.54
3.06
6.2
3.1
1.78
2.71
mmol/l
—
6
28
50
337
1.97
2.78
4.2
2.2
—
—
—
0
0
7
14
5.29
2.78
1.1
1.5
—
—
—
0
0
7
14
5.29
2.78
1.1
1.5
—
—
—
0
0
6
11
5.72
2.58
1.5
1.3
—
—
—
0
0
5
7
7.44
2.58
1.2
1.1
—
—
—
0
0
5
7
7.44
2.58
1.2
1.1
—
—
—
0
0
5
7
7.44
2.58
1.2
1.1
—
—
—
0
0
5
7
7.44
2.58
1.2
1.1
—
—
—
0
0
41
265
1.93
2.52
6.5
3.1
—
—
—
0
0
5
8
6.50
2.40
1.2
1.1
—
—
—
0
0
5
8
6.50
2.40
1.2
1.1
—
—
—
0
0
11
41
2.89
2.29
1.9
1.3
—
—
—
0
0
17
81
2.32
2.28
4.3
4.6
213.18
218.97
u/l
0.18
17
76
92
812
2.66
2.24
26.9
10.8
17.57
23.37
mg/l
1.55
78
604
5
9
5.78
2.24
1.4
1.1
—
—
—
0
0
9
30
3.19
2.21
10.2
3.5
25.19
25.56
mmol/l
—
9
30
8
25
3.39
2.14
1.4
1.5
—
—
—
0
0
29
175
1.93
2.14
4.4
1.8
—
—
—
0
0
7
20
3.68
2.09
2.1
1.5
1.14
1.19
g/l
—
7
20
14
65
2.34
1.99
2.6
1.6
—
—
—
0
0
14
66
2.30
1.92
2.6
1.7
—
—
—
0
0
5
12
4.32
1.84
3.2
1.7
—
—
—
0
0
5
12
4.32
1.84
1.4
1.8
—
—
—
0
0
5
12
4.32
1.84
1.2
1.3
—
—
—
0
0
9
36
2.65
1.79
2.1
2.6
1.31
1.31
%
—
9
36
29
188
1.76
1.68
4.9
2.6
361.55
3583.49
umol/l
0.78
29
168
21
124
1.88
1.63
1.0
1.2
19.72
28.17
iu/ml
—
6
47
5
14
3.70
1.63
4.0
1.5
—
—
—
0
0
5
14
3.70
1.63
3.6
1.6
—
—
—
0
0
38
270
1.66
1.58
5.8
3.3
27.70
76.71
ng/l
1.42
29
181
19
110
1.90
1.56
1.5
1.5
763.00
1189.78
nmol/l
1.45
13
84
5
15
3.45
1.54
7.0
1.6
—
—
—
0
0
16
88
1.97
1.52
11.6
4.4
1.09
1.03
mmol/l
0.26
16
80
38
276
1.61
1.43
1.9
1.6
98.28
95.61
pmol/l
0.12
21
138
17
98
1.89
1.42
3.4
1.9
—
—
—
0
0
5
20
2.58
1.16
1.0
1.1
—
—
—
0
0
5
20
2.58
1.16
1.0
1.2
—
—
—
0
0
5
21
2.45
1.10
1.2
1.3
—
—
—
0
0
18
115
1.69
1.09
1.1
1.2
60.42
2.68
u/ml
—
5
41
5
22
2.34
1.04
1.0
1.1
—
—
—
0
0
5
22
2.34
1.04
1.0
1.1
—
—
—
0
0
13
78
1.77
0.97
4.5
4.6
105.62
105.05
mmol/l
0.22
13
78
6
27
2.30
0.95
3.7
1.6
—
—
—
0
0
30
226
1.47
0.91
3.3
3.7
15.22
6.86
mg/mmol
0.28
21
146
6
34
1.81
0.77
1.5
1.6
—
—
—
0
0
5
24
2.14
0.75
1.4
1.5
—
—
—
0
0
5
24
2.14
0.75
1.0
1.1
—
—
—
0
0
5
25
2.05
0.74
3.6
2.5
—
—
—
0
0
66
587
1.37
0.72
3.1
3.6
14.57
14.69
pmol/l
0.14
59
534
5
26
1.97
0.71
3.2
2.2
—
—
—
0
0
89
835
1.60
0.70
26.0
12.1
139.34
139.81
mmol/l
0.99
89
806
5
30
1.70
0.62
1.2
1.1
26.00
39.13
nmol/l
—
5
30
89
840
1.54
0.62
26.3
12.1
3.97
3.96
mmol/l
0.09
89
811
0
21
0.00
0.61
0.0
1.4
—
—
—
0
0
0
21
0.00
0.61
0.0
1.4
—
—
—
0
0
0
21
0.00
0.61
0.0
1.4
—
—
—
0
0
0
23
0.00
0.59
0.0
1.6
—
—
—
0
0
11
75
1.52
0.53
3.5
2.6
—
—
—
0
0
16
123
1.36
0.44
7.9
2.9
0.85
0.82
mmol/l
0.32
16
118
92
888
1.45
0.40
28.5
12.8
85.75
76.44
umol/l
0.52
92
888
39
344
1.22
0.38
3.6
2.2
90.02
137.89
ug/l
1.02
39
312
59
543
1.21
0.37
3.9
3.0
—
—
—
0
0
6
41
1.49
0.37
1.0
1.4
—
—
—
0
0
6
41
1.49
0.37
1.3
1.4
—
172.41
iu/ml
—
0
19
6
89
0.65
0.34
22.7
6.1
—
—
—
0
0
84
806
1.26
0.31
4.3
3.7
1.48
1.26
mmol/l
2.02
78
733
7
54
1.32
0.31
3.7
3.9
1.25
1.22
mmol/l
—
7
49
83
797
1.24
0.29
20.4
10.4
83.76
84.15
ml/min/173m2
0.04
74
646
16
132
1.25
0.28
2.1
3.3
2.47
2.45
mmol/l
0.23
11
116
8
66
1.23
0.27
1.3
1.6
—
—
—
0
0
11
87
1.30
0.25
6.6
2.2
16.50
7.42
umol/l
0.33
11
74
9
76
1.20
0.25
1.4
1.8
—
—
—
0
0
19
218
0.84
0.22
2.6
3.4
22.90
22.28
%
—
7
98
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
13.17
—
0
12
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
22
197
1.15
0.17
2.1
1.6
1.77
1.39
mmol/l
0.68
15
163
8
69
1.17
0.17
7.5
5.0
1.60
1.46
mmol/l
—
8
53
84
857
0.88
0.12
4.9
4.5
2.86
2.82
mmol/l
0.13
78
783
9
102
0.87
0.06
1.4
1.8
—
—
—
0
0
85
838
1.10
0.06
4.7
4.1
4.72
4.74
mmol/l
0.04
79
771
25
263
0.93
0.06
3.9
4.0
1.28
3.15
ug/l
0.91
20
236
16
149
1.09
0.05
1.3
1.5
—
—
—
0
0
74
751
0.94
0.04
4.2
4.1
1.78
1.86
mu/l
0.19
69
679
84
834
1.04
0.00
4.7
4.0
1.40
1.48
mmol/l
1.24
78
761
77
765
1.03
0.00
6.0
5.3
39.30
39.67
mmol/mol
0.15
72
709
11
115
0.95
0.00
1.6
1.4
—
—
—
0
0
94
938
1.04
0.00
38.4
16.4
135.02
137.51
g/l
0.78
94
920
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1612.40
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.5
—
6.83
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
94
937
1.05
-0.00
37.8
16.2
40.77
40.71
%
0.04
88
893
7
72
0.97
-0.00
3.3
1.8
8.93
14.77
nmol/l
—
7
66
Mortality – FinRegistry
↥Association
Association between endpoint M13_LORDOSIS and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_LORDOSIS | 1.788 [1.23, 2.6] | 0.002 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 68 out of 251 males with M13_LORDOSIS died.
Mortality risk
Mortality risk for people of age
years, who have M13_LORDOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.306% |
| 5 | No data | 1.995% |
| 10 | No data | 5.138% |
| 15 | No data | 9.005% |
| 20 | No data | 15.167% |
Relationships between endpoints
↥Index endpoint: M13_LORDOSIS – Lordosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data